Japan: Researchers have found in a cohort study that waiting ≥43 days from diagnosis of upper tract urothelial carcinoma to radical nephroureterectomy was associated with worse overall survival in the primary analysis. However, continuous analyses did not demonstrate a consistent linear relationship. Therefore, approximately 6 weeks should be considered a hypothesis-generating benchmark rather than a universal surgical threshold.

Upper tract urothelial carcinoma (UTUC) is a relatively uncommon malignancy arising in the lining of the renal pelvis and ureter. Radical nephroureterectomy (RNU), involving removal of the kidney, ureter and part of the bladder, is an established surgical treatment for patients with localized high-risk disease. The optimal interval between diagnosis and surgery, however, remains uncertain.
To investigate whether surgical timing could influence outcomes, Yusuke Motoki, Department of Urology and Andrology, Kansai Medical University, Japan, and colleagues retrospectively evaluated 435 patients with UTUC who underwent RNU without neoadjuvant chemotherapy between June 2004 and December 2022.
In the study, published in Clinical Genitourinary Cancer, the researchers used a time-dependent receiver operating characteristic (ROC) analysis to identify a potential waiting-time cutoff. Patients were subsequently divided into an early-surgery group, undergoing RNU within the identified interval, and a delayed-surgery group. Statistical differences between the groups were addressed using inverse probability of treatment weighting, with overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) assessed.
The analysis identified 43 days as the candidate cutoff, resulting in 217 patients undergoing surgery within 43 days and 218 patients waiting 43 days or longer.
After adjustment, the delayed-surgery group had significantly poorer overall survival compared with the early-surgery group:
  • Overall survival: Delayed surgery was associated with a higher risk of death (HR 1.43).
  • Cancer-specific survival: No statistically significant difference was observed (HR 1.39).
  • Recurrence-free survival: The difference also did not reach statistical significance (HR 1.44).
  • Tumor upstaging: Progression from clinical
The findings suggest that prolonged waiting before definitive surgery may be associated with poorer survival in patients with UTUC. However, the researchers emphasized that the 43-day threshold should not be interpreted as a fixed treatment deadline.
The study's continuous-variable analyses did not demonstrate a consistent linear relationship between increasing surgical waiting time and survival outcomes. The retrospective design and single-study setting also mean that the findings require confirmation in other patient populations.
Overall, the study identifies approximately six weeks as a potential benchmark for evaluating surgical timing in UTUC, rather than establishing a universal cutoff. External validation and prospective studies are needed to determine whether reducing delays before RNU can improve outcomes.
Reference:
Motoki, Y., Sano, T., Yoshida, T., Nakamoto, T., Ikeda, J., Yoshida, R., Taguchi, M., Mishima, T., Taniguchi, H., Yanishi, M., & Kinoshita, H. (2026). Prolonged Surgical Waiting Time for Radical Nephroureterectomy is Associated with Worse Survival Outcomes in Patients with Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 102670. https://doi.org/10.1016/j.clgc.2026.102670
Tags:    
Article Source : Clinical Genitourinary Cancer

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .